Oct. 27, 2014, 9:10 AM
- Sarepta Therapeutics (NASDAQ:SRPT) plunges 39% premarket on robust volume after its announcement that the FDA requires additional data for its eteplirsen NDA including the results from an independent assessment of dystrophin images and the 168-week clinical data from study 202.
- The agency wants more information including a minimum duration of safety in new patients exposed to eteplirsen, patient-level natural history data to be obtained by Sarepta from independent academic institutions and MRI data from a recent study conducted by an independent academic group.
- The FDA has also specified that further discussions will be necessary to determine what will constitute a complete NDA.
- Sarepta now believes that it will be able to submit the NDA by mid-year 2015.
Oct. 24, 2014, 4:48 AM
- Mali has confirmed its first case of Ebola, becoming the sixth West African country to report a case of the virus.
- The patient, a 2-year-old girl who had come from neighboring Guinea, was brought to a hospital in the Malian town of Kayes.
- Mali is Africa’s third-largest gold producer.
- Related gold stocks: GOLD -2.3% premarket; AU
- Ebola Small-cap Index: HEB, TKMR, NLNK, NNVC, INO, OTCQB:GOVX, SRPT, CMRX, PLX, NSPH, BCRX, LAKE, APT, VSR, SMED.
Oct. 23, 2014, 9:57 PM
- The physician - who lives in Upper Manhattan - had returned to NYC ten days ago after treating Ebola patients in West Africa. Late in the trading session today, stocks gave back some of their big gains on a report he had been hospitalized with Ebola-type symptoms.
- City officials are at work tracing the doctor's contacts to determine who else may be at risk, and his girlfriend is being tested for the disease.
- S&P 500 (NYSEARCA:SPY) futures are lower by 0.5%.
- Ebola Small-cap Index: HEB. TKMR, NLNK, NNVC, INO, OTCQB:GOVX, SRPT, CMRX, PLX, NSPH, BCRX, LAKE, APT, VSR, SMED.
Oct. 23, 2014, 3:49 PM
- The Ebola Small Cap Index is mostly up today after a report that a potentially infected patient is under quarantine in New York.
- (HEB -0.7%)(TKMR +2.9%)(NLNK -1.5%)(NNVC +1.8%)(INO +2.6%)(OTCQB:GOVX -9.1%)(SRPT +3.5%)(CMRX +4.7%)(PLX +1.7%)(NSPH +1.8%)(BCRX +4.2%)(LAKE +18.7%)(APT +5.6%)(VSR +6.1%)(SMED +3.3%)
Oct. 17, 2014, 1:35 PM
- In a purely political move, President Obama appoints former VP Joe Biden Chief of Staff Ron Klain to the post of Ebola "czar." No one knows for sure what the lawyer will do in the post since he knows next to nothing about Ebola, the scientific basis for the spread of highly contagious diseases and infection control protocols and procedures. He probably looks good on television, though.
- The Ebola Small Cap Index is mostly down today: (HEB -1.7%)(TKMR -3.4%)(NLNK -11.3%)(NNVC -1.1%)(INO +3.9%)(OTCQB:GOVX -6.9%)(SRPT +3.7%)(CMRX -1.7%)(PLX -3%)(NSPH -5.5%)(BCRX -5.4%)(LAKE -13.5%)(APT -16.8%)(VSR -21.7%)(SMED -7.3%)
- ETFs: IRY, IXJ
Oct. 17, 2014, 9:20 AM
Oct. 16, 2014, 5:59 PM
- Two phase I studies "demonstrated no clinical or toxicologic safety concerns" for Sarepta's (NASDAQ:SRPT) AVI-6002 and AVI-6003 drug candidates, respectively meant to treat Ebola and Marburg virus. (PR)
- Results "showed the compounds to be well-tolerated with no dose limiting level demonstrated." Both AVI-6002 and AVI-6003 are combination therapies.
Oct. 16, 2014, 5:37 PM
Oct. 16, 2014, 3:37 PM
- Prosensa Holding N.V. (RNA +5.5%) commences its NDA submission process with the FDA for drisapersen for the treatment of Duchenne muscular dystrophy (DMD). The agency will review the application on a rolling basis as stipulated under Fast Track. It also designated drisapersen an Orphan Drug in June 2013.
- DMD-related tickers: (SRPT +7.1%)(PTCT +1.3%)(ROSG +8%)(OTCQB:MRNA)
Oct. 16, 2014, 9:09 AM
- Nano cap (NYSEMKT:IBIO) is up 52% premaket on robust volume in apparent response to its press release about the applicability of its iBioLaunch technology to the development of antibodies that target Ebola. Over zealous traders appear to be ignoring the long-term nature of the applicability.
- As previously reported,the company licensed iBioLaunch to would-be ZMapp manufacturer Caliber Biotherapeutics.
- Ebola Small Cap Index: (NYSEMKT:HEB) (NASDAQ:TKMR) (NASDAQ:NLNK) (NYSEMKT:NNVC) (NASDAQ:INO) (OTCQB:GOVX) (NASDAQ:SRPT) (NASDAQ:CMRX) (NYSEMKT:PLX) (NASDAQ:NSPH) (NASDAQ:BCRX) (NASDAQ:LAKE) (NYSEMKT:APT) (NYSEMKT:VSR) (NASDAQ:SMED)
Oct. 15, 2014, 8:57 AM
- The report of a second Ebola infection at the Texas hospital that treated Thomas Eric Duncan has traders clamoring for Ebola-related stocks this morning.
- Premarket moves for the Ebola Small Cap Index: (NYSEMKT:IBIO): +4%; (NYSEMKT:HEB): +5%; (NASDAQ:TKMR): +4%; (NASDAQ:NLNK): +6%; (NYSEMKT:NNVC): +1%; (NASDAQ:INO): +0.4%; (NASDAQ:BCRX): +5%; (OTCQB:GOVX): n/a; (NASDAQ:SRPT): +2%; (NASDAQ:CMRX): +4%; (NYSEMKT:PLX): +2%; (NASDAQ:NSPH): +5%; (NASDAQ:SMED): +6%; (NASDAQ:LAKE): +15%: (NYSEMKT:APT): +20%; (NYSEMKT:VSR): +37%.
- LAKE, APT and VSR are the only ones up on high volume.
Oct. 15, 2014, 5:25 AM
- A second healthcare worker has contracted Ebola in the U.S.,
- The worker, a staff member at Texas Health Presbyterian Hospital, was among those who looked after Thomas Duncan, who died of the virus earlier this month.
- More on Ebola
- Related health stocks: TKMR, BCRX, HEB, INO, NLNK, NNVC, OTCQB:GOVX, SRPT, CMRX, GSK, IBIO, APT, LAKE, SRPT, PLX, NSPH, SMED, VSR, AHPI
- Airlines: DAL, AAL, UAL, SKYW, ALGT, HA, LUV
- Hotels: MAR, HLT, IHG, STAY, H, HOT, CHH
- Lodging REITS: AHT, SHO, LHO, INN
Oct. 14, 2014, 12:04 PM
- Most members of the unofficial Ebola Small Cap Index are holding up in today's trading. Ibio and Nanosphere are the only ones getting roughed up.
- (IBIO -24.5%)(HEB -8%)(TKMR +1.7%)(NLNK +9.5%)(NNVC +6.7%)(INO +3.9%)(BCRX +5.5%)(OTCQB:GOVX +17.9%)(SRPT +5%)(CMRX +1.2%)(PLX -4.1%)(NSPH -39.9%)(SMED -1.6%)(LAKE -5.5%)(APT -0.5%)
Oct. 10, 2014, 4:18 PM
- Nano cap Ibio (IBIO +83.7%) was up big today on a massive 13.2M shares in response to reports that it may be a player in the government's efforts to ramp up production of Mapp Biopharmaceuticals' Ebola drug ZMapp.
- Ibio, working with Fraunhofer Center for Molecular Biotechnology, developed a plant-based technology called iBioLaunch that can bring vaccines to market more rapidly.
- The government is in advanced discussions with Caliber Biotherapeutics on the initiative. Caliber can produce ZMapp in large quantities utilizing its plant-based capabilities and Ibio's iBioLaunch technology which Caliber licensed last year. iBioLaunch causes green plants to produce commercial quantities of targeted human proteins in proper form for use in pharmaceuticals.
- Under the terms of the license agreement, Ibio will receive license and milestone fees based on the development of product targets selected by Caliber.
- Ebola-related tickers: (TKMR -4.3%)(BCRX -6.3%)(HEB +11.1%)(INO -0.5%)(NLNK -2%)(OTCQB:GOVX -15.7%)(SRPT -5.4%)(CMRX -2.4%)
Oct. 9, 2014, 1:52 PM
- Protective clothing maker Alpha Pro Tech (APT +19%) continues its Ebola-stoked up move today. Shares of the thinly-traded nano cap have more than doubled in two months.
- Protective gear compatriot Lakeland Industries (LAKE +58.1%) also zooms up on a massive 33M shares.
- Ebola drug makers aren't faring as well. The "Ebola Small Cap Index" is in the red:
- (TKMR -4.4%)(BCRX -4.2%)(HEB -4.7%)(INO -4%)(NLNK -6.2%)(NNVC -3.4%)(OTCQB:GOVX -6.8%)(SRPT -5.2%)(CMRX -3.6%)
Oct. 1, 2014, 9:12 AM
SRPT vs. ETF Alternatives
Other News & PR